Abstract

Background and Purpose. Fibroblast growth factor 21 (FGF21) has recently been identified as a metabolic regulator, but its physiological role is still not completely known. The aim of this study was to evaluate serum FGF21 levels in an Iranian population with type 2 diabetes. Materials and Methods. This cross-sectional study was conducted in patients with type 2 diabetes. All patients were evaluated for fasting serum levels of glucose, glycated hemoglobin (HbAlc), lipids, urea and creatinine. Participants were divided into two groups with poorly-controlled and well controlled diabetes based on their HbAlc levels. Healthy non diabetic subjects (matched with patients in terms of age, sex and body mass index BMI) were also recruited as control group. Serum FGF21 concentrations were determined in all subjects using ELISA . Results. Of the evaluated 141 subjects, 49 (34.8%) were categorized as having well-controlled diabetes, 66 (46.8%) had poorly-controlled diabetes, and there were 26 subjects in the normal control group. Mean serum FGF-21 concentration was 337.89 +/- 283.67 ng/L in the diabetic group and 237.25 +/- 43.22 ng/mL in the non-diabetic group (p<0.001). Mean serum FGF21 level was 237.25 +/- 43.22 ng/mL in the control group, 309.81 +/- 301.68 ng/mL in the well-controlled diabetic group, and 358.73 +/- 269.98 ng/mL in the poorly controlled diabetic group. Serum FGF21 level in the poorly controlled diabetic group was significantly higher than that in the well-controlled diabetic and the healthy control groups (p=0.02) but there was no significant difference between the well-controlled and healthy groups. There was no significant association between serum FGF21 levels with lipid levels, presence of diabetic complications and BMI (p > 0.05). Conclusions. The present results suggested an association between elevated serum levels of FGF21 and poor control of diabetes. Future studies are warranted to elucidate the prognostic role of these elevated levels of FGF21 in diabetic subjects.